Implementing laboratory automation for next-generation sequencing: benefits and challenges for library preparation.
automation
next-generation sequencing
public health
validation
verification
Journal
Frontiers in public health
ISSN: 2296-2565
Titre abrégé: Front Public Health
Pays: Switzerland
ID NLM: 101616579
Informations de publication
Date de publication:
2023
2023
Historique:
received:
28
03
2023
accepted:
15
06
2023
medline:
1
8
2023
pubmed:
31
7
2023
entrez:
31
7
2023
Statut:
epublish
Résumé
In the wake of COVID-19, the importance of next-generation sequencing (NGS) for diagnostic testing and surveillance-based screening has never been more evident. Considering this, continued investment is critical to ensure more public health laboratories can adopt these advanced molecular technologies. However, many facilities may face potential barriers such as limited staff available to routinely prepare, test, and analyze samples, lack of expertise or experience in sequencing, difficulties in assay standardization, and an inability to handle throughput within expected turnaround times. Workflow automation provides an opportunity to overcome many of these challenges. By identifying these types of sustainable solutions, laboratories can begin to utilize more advanced molecular-based approaches for routine testing. Nevertheless, the introduction of automation, while valuable, does not come without its own challenges. This perspective article aims to highlight the benefits and difficulties of implementing laboratory automation used for sequencing. We discuss strategies for implementation, including things to consider when selecting instrumentation, how to approach validations, staff training, and troubleshooting.
Identifiants
pubmed: 37521966
doi: 10.3389/fpubh.2023.1195581
pmc: PMC10373871
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1195581Informations de copyright
Copyright © 2023 Socea, Stone, Qian, Gibbs and Levinson.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Front Microbiol. 2020 Aug 05;11:1883
pubmed: 32849463
J Pers Med. 2018 Sep 17;8(3):
pubmed: 30227640
Arch Pathol Lab Med. 2015 Apr;139(4):481-93
pubmed: 25152313
Front Cell Infect Microbiol. 2021 Mar 11;11:632490
pubmed: 33777844
Clin Chem. 2021 Dec 30;68(1):99-114
pubmed: 34969105
Antimicrob Agents Chemother. 2019 May 24;63(6):
pubmed: 30910904
J Clin Microbiol. 2017 Aug;55(8):2502-2520
pubmed: 28592550
J Clin Microbiol. 2016 Dec;54(12):2857-2865
pubmed: 27510831